EUVIMEDEUVIMED entdecken
Crossref

Salvianolic acid a inhibits neuroinflammation and ameliorates Alzheimer's disease pathology via the p38 MAPK/NF-κB pathway based on network pharmacology and experimental validation

Shifeng Xiao, Yuping Han, Ji Yan, Lijuan Wu, Haitong Lin, Cuiyi Yuan, Changjie Song, Jinwang Ye

International Immunopharmacology · 2026-06 · 178 · 116594

DOI: 10.1016/j.intimp.2026.116594 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2026-06. Verfasst von Shifeng Xiao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Key Laboratory of Marine Biotechnology and Ecology, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518060, China; …. Hauptthemen laut MEDLINE: Alzheimer Disease, Anti-Inflammatory Agents, Caffeic Acids, Lactates. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Shenzhen Science and Technology Innovation Commission, National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) represents the most prevalent form of neurodegenerative disorder, characterized by progressive cognitive impairments and a scarcity of effective treatments. Salvianolic acid A (SalA), a natural phytochemical endowed with antioxidative, antiapoptotic, and anti-inflammatory properties, emerges as a promising therapeutic candidate for AD. This study explored the therapeutic efficacy and underlying mechanisms of SalA in mitigating AD-related pathologies. Through integrative network pharmacology, molecular docking, and pathway enrichment analysis, p38 MAPK and NF-κB were identified as potential targets of SalA in the context of AD. SalA treatment inhibited the activation of the p38 MAPK/NF-κB pathway via targeting p38 MAPK, leading to decreased levels of IL-1α and IL-1β in lipopolysaccharide (LPS)-stimulated HMC3 cells. In an in vivo 3 × Tg-AD mouse model, SalA administration ameliorated cognitive decline associated with AD, decreased tau protein hyperphosphorylation in the hippocampus and cortex, and reduced amyloid-β (Aβ) accumulation and β-site amyloid precursor protein cleaving enzyme 1 (BACE1) levels. Furthermore, SalA attenuated the activation of the p38 MAPK/NF-κB pathway and the expression of related inflammatory cytokines in the brains of 3 × Tg-AD mice. In conclusion, this study elucidates the promising ameliorative effects of SalA on improving AD pathology, primarily through the modulation of the p38 MAPK/NF-κB signaling pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAnti-Inflammatory AgentsCaffeic AcidsLactatesNeuroinflammatory DiseasesNF-kappa BMitogen-Activated Protein Kinase 14AnimalsFemaleHumansMiceAmyloid beta-PeptidesCerebral CortexDisease Models, AnimalHippocampusMemoryMice, Inbred C57BLMice, TransgenicMolecular Docking SimulationNetwork PharmacologySignal Transductiontau ProteinsMicroglia

Stichwörter der Autor:innen

Alzheimer's diseaseNF-κBNetwork pharmacologySalvianolic acid ap38 MAPK

Substanzen

Amyloid beta-PeptidesAnti-Inflammatory AgentsCaffeic AcidsLactatesNF-kappa Bsalvianolic acid AMitogen-Activated Protein Kinase 14tau Proteins

Autor:innen und Institutionen

  • Shenzhen Key Laboratory of Marine Biotechnology and Ecology, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518060, China; Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Res…
  • Shenzhen Key Laboratory of Marine Biotechnology and Ecology, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518060, China.

Förderung

  • Shenzhen Science and Technology Innovation Commission
  • National Natural Science Foundation of China
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Shenzhen-Hong Kong Institute of Brain Science

Zitieren

APA

Xiao, S., Han, Y., Yan, J., Wu, L., Lin, H., Yuan, C., Song, C., & Ye, J. (2026). Salvianolic acid a inhibits neuroinflammation and ameliorates Alzheimer's disease pathology via the p38 MAPK/NF-κB pathway based on network pharmacology and experimental validation. International Immunopharmacology, 178, 116594. https://doi.org/10.1016/j.intimp.2026.116594

Vancouver

Xiao S, Han Y, Yan J, Wu L, Lin H, Yuan C, et al. Salvianolic acid a inhibits neuroinflammation and ameliorates Alzheimer's disease pathology via the p38 MAPK/NF-κB pathway based on network pharmacology and experimental validation. International Immunopharmacology. 2026;178:116594. doi:10.1016/j.intimp.2026.116594

BibTeX
@article{Xiao2026,
  author = {Xiao, Shifeng and Han, Yuping and Yan, Ji and Wu, Lijuan and Lin, Haitong and Yuan, Cuiyi and Song, Changjie and Ye, Jinwang},
  title = {Salvianolic acid a inhibits neuroinflammation and ameliorates Alzheimer's disease pathology via the p38 MAPK/NF-κB pathway based on network pharmacology and experimental validation},
  journal = {International Immunopharmacology},
  year = {2026},
  volume = {178},
  pages = {116594},
  doi = {10.1016/j.intimp.2026.116594}
}
Kostenlos starten →